Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
PRO-143
- Development stage
- Discontinued
- Lead developer
- Lantheus
- Administration
- Ophthalmic
01
Overview
PRO-143 is an investigational ophthalmic solution that has been evaluated in clinical studies for safety and tolerability in healthy volunteers. The specific mechanism of action, molecular target, and therapeutic indication are not publicly disclosed. Available information indicates it is being developed as an eye drop formulation, but no further details on its pharmacological class or intended disease area have been published[3].
Beyond the preview
Go deeper on PRO-143.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on PRO-143.